Yiyi Ji

489 total citations
13 papers, 309 citations indexed

About

Yiyi Ji is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Yiyi Ji has authored 13 papers receiving a total of 309 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 6 papers in Molecular Biology and 4 papers in Cancer Research. Recurrent topics in Yiyi Ji's work include Prostate Cancer Treatment and Research (8 papers), Epigenetics and DNA Methylation (3 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Yiyi Ji is often cited by papers focused on Prostate Cancer Treatment and Research (8 papers), Epigenetics and DNA Methylation (3 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Yiyi Ji collaborates with scholars based in China and United States. Yiyi Ji's co-authors include Wei Xue, Weiwei Zhang, Zehua Ma, Jiahua Pan, Baijun Dong, Qi Wang, Zhixiang Xin, Kai Shen, Kai Shen and Xun Shangguan and has published in prestigious journals such as Nature Communications, International Journal of Cancer and Molecules.

In The Last Decade

Yiyi Ji

10 papers receiving 309 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yiyi Ji China	7	166	105	99	85	51	13	309
Xinjian Huang China	13	190 1.1×	112 1.1×	68 0.7×	172 2.0×	40 0.8×	25	395
Zehua Ma China	8	162 1.0×	124 1.2×	102 1.0×	83 1.0×	47 0.9×	13	311
Frank Duong United States	9	151 0.9×	101 1.0×	108 1.1×	119 1.4×	50 1.0×	14	302
Silvia Esposito Italy	9	153 0.9×	77 0.7×	81 0.8×	123 1.4×	75 1.5×	9	296
Samaneh Adelian Iran	10	202 1.2×	126 1.2×	48 0.5×	84 1.0×	45 0.9×	13	310
Tongmei Zhang China	11	138 0.8×	123 1.2×	96 1.0×	219 2.6×	62 1.2×	49	389
Xinrui Rao China	11	159 1.0×	67 0.6×	39 0.4×	86 1.0×	59 1.2×	19	270
May Elbanna United States	7	136 0.8×	63 0.6×	85 0.9×	72 0.8×	47 0.9×	16	252
Fujiang Xu China	7	180 1.1×	92 0.9×	96 1.0×	49 0.6×	31 0.6×	13	281
Guiqi Zhu China	8	147 0.9×	137 1.3×	83 0.8×	128 1.5×	89 1.7×	13	376

Countries citing papers authored by Yiyi Ji

Since Specialization

Citations

This map shows the geographic impact of Yiyi Ji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yiyi Ji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yiyi Ji more than expected).

Fields of papers citing papers by Yiyi Ji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yiyi Ji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yiyi Ji. The network helps show where Yiyi Ji may publish in the future.

Co-authorship network of co-authors of Yiyi Ji

This figure shows the co-authorship network connecting the top 25 collaborators of Yiyi Ji. A scholar is included among the top collaborators of Yiyi Ji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yiyi Ji. Yiyi Ji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Zhang, Weiwei, Yiyi Ji, Xinyu Liu, et al.. (2025). Targeting the CCL5/CCR5 axis in tumor-stromal crosstalk to overcome cisplatin resistance in neuroendocrine prostate cancer. Journal of Experimental & Clinical Cancer Research. 44(1). 296–296.

Chen, Tianyi, Xiaorong Pu, Junyao Xu, et al.. (2025). Osalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3/BCL-XL pathway. Cancer Letters. 613. 217514–217514. 2 indexed citations

Zhang, Zhuo, Qianqian Shen, Yiyi Ji, et al.. (2024). Structural Optimization of Isoquinoline Derivatives from Lycobetaine and Their Inhibitory Activity against Neuroendocrine Prostate Cancer Cells. Molecules. 29(18). 4503–4503.

Li, Ang, Kai Shen, Yiyi Ji, et al.. (2024). Prognostic value of [ ¹⁸ F]FDG PET/CT in metastatic hormone-sensitive prostate cancer at initial diagnosis: a retrospective cohort study. Annals of Medicine. 56(1). 2411017–2411017.

Ji, Yiyi, Xiang Zhou, Bo Liu, et al.. (2023). ¹⁸F‐FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis. The Prostate. 83(12). 1167–1175. 3 indexed citations

Ji, Yiyi, Bo Liu, Lei Chen, et al.. (2023). Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway. Cellular Oncology. 46(5). 1445–1456. 10 indexed citations

Chen, Lei, Yiyi Ji, Ang Li, et al.. (2023). High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer. Frontiers in Oncology. 13. 1085569–1085569. 5 indexed citations

Liu, Hailong, Yiyi Ji, Zehua Ma, et al.. (2022). Downregulation of SHMT2 promotes the prostate cancer proliferation and metastasis by inducing epithelial-mesenchymal transition. Experimental Cell Research. 415(2). 113138–113138. 15 indexed citations

Ma, Zehua, Weiwei Zhang, Baijun Dong, et al.. (2022). Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics. 12(11). 4965–4979. 80 indexed citations

10.

Chen, Lei, Zhou Jiang, Weiwei Zhang, et al.. (2022). Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation. Frontiers in Oncology. 12. 955166–955166. 9 indexed citations

11.

Shangguan, Xun, Jianli He, Zehua Ma, et al.. (2021). SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis. Nature Communications. 12(1). 1812–1812. 117 indexed citations

12.

Shen, Kai, Bo Liu, Xiang Zhou, et al.. (2021). The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer. Frontiers in Oncology. 11. 683793–683793. 30 indexed citations

13.

Xu, Fan, Xun Shangguan, Jiahua Pan, et al.. (2021). HOXD13 suppresses prostate cancer metastasis and BMP4‐induced epithelial‐mesenchymal transition by inhibiting SMAD1. International Journal of Cancer. 148(12). 3060–3070. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact